Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment ...( DALLAS Nov. 6 /- Access Pharmaceu...)
| HOME >> BIOLOGY >> TECHNOLOGY |
DALLAS, Nov. 6 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced today that it will make a presentation at the Rodman & Renshaw Annual Global Investment Conference to be held November 10-12, 2008 at the New York Palace Hotel. Jeffrey B. Davis, CEO of Access is scheduled to speak on Tuesday, November 11, 2008 at 2:50 p.m. Eastern Time, and will give a corporate overview and discuss the Company's product opportunities.
The presentation will be available via webcast and can be accessed at: http://www.wsw.com/webcast/rrshq14/accp.ob. The replay can be obtained at the same link for 90 days.
About ProLindac(TM):
ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion.
About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company
that develops and commercializes propriety products for the treatment and
supportive care of cancer patients. Access' products include Prodac(TM),
currently in Phase 2 clinical testing of patients with ovarian cancer, and
MuGard(TM) for the management of patients with mucositis. The company also
has other advanced drug delivery technologies including
Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its
proprietary nanopolymer delivery technology based on the natural vitamin
B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which
acts as an anti-angiogenesis factor and is targeted to breast cancer;
Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of
solid tumors to kill cancer cells; Alchemix, a chemotherapeuti
'/>"/>
| SOURCE Access Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
3. Mymetics Corporation Information to be Available Through Standard & Poors Market Access Program
4. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
5. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
6. NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population
7. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
10. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
11. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |